I N T R O D U C T I O N
Na/K-ATPase is a P-type ATPase capable of transporting sodium and potassium against their concentration gradients [1] . It has been established that four isoforms of the a subunit of Na/K-ATPase exist-of note, the a1 isoform is expressed ubiquitously, while the a2 isoform is predominately found in skeletal muscle [2] . Interestingly, studies from our group and others have demonstrated that in addition to its role as an ion transporter, the a1 isoform can form a functional signaling complex with Src, a non-receptor tyrosine kinase, which is known to be involved in numerous signaling cascades [3] . This Na/K-ATPase/Src signaling complex can be activated by the binding of cardiotonic steroids (CTSs) [4] [5] [6] . However, some controversy still exists regarding whether Na/K-ATPase and Src directly interact within this complex [7] .
CD40, a type I transmembrane receptor of the toll-like receptor superfamily, was initially discovered as a mediator of humoral immune reactions [8] . However, it is now understood that CD40 is widely expressed, including within renal proximal tubular epithelial cells, and may serve broader functions [9, 10] . Interestingly, we have previously shown that circulating levels of the ligand for CD40, soluble CD40 ligand (sCD40L), are significantly increased in subjects with renal artery stenosis [11] . Follow-up studies have identified circulating CD40 mediators as predictive of changes in renal function in subjects with renal artery stenosis [12] and chronic kidney disease [13] . Furthermore, we have recently demonstrated that functional deletion of CD40 in a strain of rat prone to kidney disease improved renal function and attenuated renal fibrosis [14] . However, little is currently understood about the regulation of CD40 in the setting of renal disease.
Recent studies have established a critical role of the Na/K-ATPase/Src signaling complex in the regulation of cellular signaling pathways important for reactive oxygen species (ROS) generation, inflammation and fibrosis in the kidney [15] [16] [17] . Given that both Na/K-ATPase and CD40 play central roles in mediating renal fibrosis and are known to reside in caveolae [18, 19] , we speculate that Na/K-ATPase may crosstalk and be critically involved in the regulation of CD40 within renal parenchyma. Demonstration of a relationship between Na/KATPase and CD40 would reveal the existence of a profibrotic feed-forward signaling loop and identify a new pharmacological target for the treatment of renal fibrosis.
M A T E R I A L S A N D M E T H O D S

Materials
Rabbit anti-CD40 antibody (#13545) was purchased from Abcam (Cambridge, MA, USA). Mouse anti-a2 antibody (AB9094-I) was purchased from EMD Millipore (Billerica, MA, USA). Mouse anti-a1 antibody (a6F) was from the Developmental Studies Hybridoma Bank at the University of Iowa (Iowa City, IA, USA). Rabbit anti-caveolin-1 antibody (D46G3) was purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse anti-a-tubulin (TU-02), mouse anti-c-Src (B-12) and all horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA) Telocinobufagin (TCB) was purchased from Baoji Herbest Bio-tech (Baoji City, China). pNaKtide was synthesized and purchased from Ohio Peptide (Columbus, OH, USA). Materials for sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Dulbecco's modified Eagle medium (DMEM) with L-glutamine, 4.5 g/L glucose and sodium pyruvate was purchased from Fisher Scientific (Waltham, MA, USA). Fetal bovine serum (FBS) was purchased from Rocky Mountain Biologicals (Missoula, MT, USA). Rabbit anti-phospho-Src (Tyr418; 44-660 G), trypsin ethylenediaminetetraacetic acid (EDTA; 0.25%) and penicillin-streptomycin (10 000 U/mL) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). sCD40L was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Recombinant human TNF-a (300-01A) was purchased from PeproTech (Rocky Hill, NJ, USA).
Cell culture
LLC-PK1 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA; CL-101). For a detailed description of the generation of stable mutant Na/K-ATPase cell lines, please see relevant publications and Table 2 [20] [21] [22] [23] . Cells were cultured in DMEM supplemented with 10% FBS with 100 U/mL penicillin and streptomycin.
Animals
Male Sprague Dawley rats were used for all of the studies. All of the animal experimentation described in the article was conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals using protocols approved by the University of Toledo, Health Science Campus, Institutional Animal Use and Care Committee. Rats weighing between 250 and 300 g (n ! 8 per group) were subjected to sham surgery, 5/6 partial nephrectomy (PNx), or minipump (ALZET model 2004, Durect, Cupertino, CA, USA) infusion of the CTS marinobufagenin (MBG) at 10 mg/kg/day inserted subcutaneously through a flank incision as described previously [24] . The animals were euthanized and tissues were collected for biochemical studies 4 weeks following treatment.
Immunoblot analysis (in vivo)
Renal cortex tissue was isolated from kidneys and homogenized in ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer (pH 7.0) (Santa Cruz Biotechnology; sc-24948). The proteins, obtained from tissue homogenates, were resolved on an SDS-PAGE using Precast Ready Gels 4-15% Tris-HCl, purchased from Bio-Rad. In all, 60 lg of protein per sample were loaded into each well. The proteins from the gel were electrotransferred to a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk in 20 mmol/L Tris-HCl (pH 7.5, 150 mmol/L NaCl and 0.1% Tween 20) . Mouse anti-CD40 antibody (Abcam) was used to probe for CD40 and secondary anti-mouse antibody was purchased from Invitrogen (Grand Island, NY, USA).
Immunoblot analysis (in vitro)
Cells were washed with cold phosphate-buffered saline (PBS) and then lysed into radioimmunoprecipitation buffer (0.25% deoxycholate, 1% Nonidet P-40, 1 mM EDTA) with 1Â Halt Protease and Phosphatase Inhibitor (Thermo Fisher, #78440). Cell lysates were vortexed and then rotated at 4 for 15 min. Cell lysates were then spun at 15 000 g for 15 min at 4 C and supernatants were transferred to a new tube. Cell lysates were stored at À80 C. Following determination of protein concentration, aliquots containing 30 lg of proteins were subjected to SDS-PAGE under reducing conditions unless otherwise noted. Proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (Thermo Fisher, #88518) and then probed using the indicted antibody.
RNA isolation and real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted using the RNEasy kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions. RNA was stored at À80 C. The concentration and purity of RNA was assessed using NanoDrop 2000 (Thermo Fisher). RNA was reverse transcribed into cDNA using the Qiagen RT 2 First Strand cDNA kit. cDNA was stored at À20 C. qPCR reactions were performed on a Qiagen Rotor Gene Q system using the Qiagen RT 2 FAST SYBR Green/ROX kit according to the manufacturer's instructions.
Primers
Species-specific primers were designed using Primer-BLAST (National Center for Biotechnology Information, Bethesda, MD, USA) and were sent to Integrated DNA Technologies (Coralville, IA, USA) for synthesis. Primer sequences can be found in Table 1 . Verification of single product amplification was assessed by analyzing melt curves as well as by running qPCR amplification products on an agarose gel.
Basal CD40 expression
Cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin. Once cells reached confluency, either RNA or protein was collected according to the protocols described above.
Effects of TCB on CD40 expression or Src kinase activity
Cells were serum starved upon reaching confluency for 16-24 h. Following serum starvation, appropriate concentrations of TCB were added to the cells for 24 h. For experiments utilizing our novel Na/K-ATPase/Src antagonist, pNaKtide, 1 mM pNaKtide was added to the cells for 30 min prior to any TCB treatments. To assess the effects of TCB on Src kinase activity, serum starved cells were incubated with the appropriate concentrations of TCB for 15 min.
Surface protein biotinylation
Cells were grown in 60-mm dishes until 90-100% confluent. Cells were washed three times with cold PBS containing 1 mM EDTA. Cells were incubated for 1 h with a total of 2.5 mL of sulfo-NHS-SS-biotin solution (Thermo Fisher, #21331), freshly diluted into biotinylation buffer (10 mM triethanolamine, pH 9.0, 250 mM sucrose). Plates were kept on ice, with gentle horizontal shaking. Cells were rinsed three times with PBS-EDTA with 100 mM glycine and then washed twice for 15 min on ice in order to quench any unbound biotin. Plates were then washed twice with cold PBS and cells were lysed in 200 mL of lysis buffer [50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 1%Triton X-100 and protein inhibitor mixture (pH 7.5)]. Cell lysates were vortexed and rotated at 4 C for 15 min. Cell lysates were then spun at 15 000 g for 15 min at 4 C. Following determination of protein concentration, microcentrifuge tubes containing 100 lg of protein, 35 lL of streptavidin agarose beads (Thermo Fisher, #20347) and lysis buffer to a final volume of 500 lL were rotated at 4 C overnight. Microcentrifuge tubes were washed five times with PBS. Laemmli loading buffer (35 lL) was added to each and samples were shaken in a 55 C water bath for 30 min to elute protein. Eluted protein was then subjected to SDS-PAGE, transferred onto a PVDF membrane and probed using the indicated antibody.
sCD40L and TNF-a treatments
The indicated cell type was serum starved for 16-24 h and treated with either 0, 25, 50 or 100 ng/mL sCD40L or 10 ng/mL TNF-a for 24 h. Following treatment, total RNA was collected and monocyte chemoattractant protein-1 (MCP-1/CCL2) gene expression was assessed.
Cellular fractionation
Subcellular fractionation was performed as previously described [25] . Briefly, cell homogenates were obtained in a 500 mM sodium carbonate (pH 11.0) solution. The sucrose content in homogenates was adjusted to 45% using 90% sucrose prepared in MBS (25 mM MES, 0.15 M NaCl, pH 6.5). Samples were placed at the bottom of an ultracentrifuge tube and loaded with 4 mL of 35% sucrose and 4 mL of 5% sucrose (both in MBS containing 250 mM sodium carbonate) and centrifuged at 39 000 rpm for 16-20 h in an SW41 rotor (Beckman Instruments, Fullerton, CA, USA). A total of 11 gradient fractions of 1 mL were collected from the top to the bottom of the centrifuge tube. Fractions 4 and 5 were combined and considered the caveolar-enriched fraction.
Cycloheximide
Cells were grown to 90-100% confluency and then incubated with 10 mg/mL cycloheximide for 24 h.
Statistical analysis
Data presented are the mean 6 standard error (SE) of the mean of at least three independent experiments. Student's unpaired t-test was used to assess statistically significant differences between two groups. One-way analysis of variance (ANOVA) and post hoc multiple comparisons tests were used when comparing more than two groups. Statistical significance was accepted as P < 0.05. All statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA).
R E S U L T S
Effects of CTS on CD40 expression
We have previously demonstrated in an in vivo system that chronic infusion of MBG, a CTS and ligand of Na/K-ATPase, causes renal fibrosis [15] . We have also shown that CTSs are increased in animals subjected to 5/6 PNx and that immunization against CTSs in the PNx model can improve renal function and attenuate renal fibrosis [16, 26] . To test whether Na/KATPase and CD40 crosstalk in the pathogenesis of renal fibrosis, we assessed kidney cortical expression of CD40 in animals infused with MBG or subjected to PNx. As illustrated in Figure  1A , both PNx and infusion of MBG led to statistically significant increases in CD40 expression in kidney cortex compared 
with sham-operated controls (P < 0.01). Kidney cortical Na/KATPase a1 expression was unaltered ( Figure 1B ). Next, in order to determine whether Na/K-ATPase is involved in the regulation of CD40 expression, we incubated LLC-PK1 cells, a pig proximal tubule epithelial cell line, for 24 h with TCB, a potent CTS known to be elevated in subjects with chronic kidney disease [27] . Moreover, it has been shown that levels of endogenous ouabain are not significantly altered in animals undergoing PNx, nor in subjects with CKD, which suggests that bufadienolides, such as TCB, may be the more physiologically relevant CTSs to use in our system [28] . By western blotting, we observed a statistically significant increase in CD40 expression with 10 nM of TCB when compared with our control group ( Figure 1C ; P < 0.01), confirming our in vivo observations with MBG. The effects of lower doses of TCB were also assessed (Supplementary data, Figure S1 ). Interestingly, our results demonstrated that TCB at both 10 and 100 nM induced increases in Src kinase activity ( Figure 1D ; P < 0.01).
Furthermore, as shown in Figure 1E , 10 nM TCB induced a statistically significant increase in the expression of a1 in LLC-PK1 cells (P < 0.05). Taken together, our data demonstrate that TCB, at physiologically relevant concentrations, induces the expression of CD40, Src kinase activity and a1 in LLC-PK1 cells.
The a1 isoform of Na/K-ATPase is an important regulator of CD40 expression
In order to further establish a role of the Na/K-ATPase a1 isoform in the regulation of CD40, we measured CD40 expression in LLC-PK1, PY-17 and AAC-19 cells. PY-17 cells are derived from LLC-PK1 and they express <10% of a1 as compared to LLC-PK1 cells (Table 2) . AAC-19 cells are PY-17 cells transfected with rat a1 cDNA [20] (Table 2) . As expected, while LLC-PK1 and AAC-19 cells expressed comparable amounts of a1, the a1 expression was barely detectable in PY-17 cells (Figure 2A) . Interestingly, knockdown of the a1 isoform of PNx and animals infused with MBG was analyzed by western blot for CD40 expression or (B) Src kinase activity. Blots were normalized using b-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control and are expressed as a fraction of the sham control. The data are presented as mean 6 SE. *P < 0.05, **P < 0.01 compared with sham. (C) LLC-PK1 cells were serum starved and treated with TCB for 24 h. CD40 expression, following treatment, was analysed by western blot. Results were normalized using a-tubulin as a loading control and are expressed as a fraction of the control. The data are presented as mean 6 SE. *P < 0.05, **P < 0.01 compared with control. (D) LLC-PK1 cells were serum starved and treated with TCB for 15 min. Src kinase activity was analysed by western blot. Blots were stripped and reprobed for total Src. Results were normalized using total Src as a loading control and are expressed as a fraction of the control. The data are presented as mean 6 SE. *P < 0.05, **P < 0.01 compared with control. (E) TCB-treated LLC-PK1 cells were probed for Na/K-ATPase a1 expression by western blot. Results were normalized using a-tubulin as a loading control and are expressed as a fraction of the control. The data are presented as mean 6 SE. *P < 0.05 compared with control.
Na/K-ATPase mediated regulation of CD40 Na/K-ATPase caused a statistically significant reduction in CD40 expression in PY-17 cells (P < 0.05). This reduction was fully recovered in AAC-19 cells. In aggregate, these results indicate that a1 is an important regulator of CD40 expression in renal epithelial cells.
To assess whether this regulation is specific to the a1 isoform of Na/K-ATPase, we measured CD40 expression in LX-a2 cells. LX-a2 cells are PY-17 cells transfected with rat a2 expressing vectors [21] (Table 2 ). As such, only the a2 isoform of Na/KATPase is detectable in LX-a2 cells. This is illustrated in the top two panels of Figure 2B . Interestingly, in contrast to AAC-19 cells, expression of a2 did not restore the expression of CD40 in LX-a2 cells. Because ouabain-sensitive ATPase activity in LX-a2 cells was comparable to that in AAC-19 cells [23] , these findings suggest that the regulatory effect of a1 Na/K-ATPase on CD40 expression is unlikely, due to changes in ion pumping capacity.
We also compared the basal Src kinase activity in these cell lines. As illustrated in Figure 2C and 2D, PY-17 and LX-a2 cells had greater levels of Src kinase activity compared with their respective controls. These findings are in accordance with what has been previously reported in the literature [20, 21] .
A functional Na/K-ATPase/Src complex is critical for regulation of CD40 expression A major difference between the a1 and a2 isoforms of Na/ K-ATPase is their ability to interact and regulate Src [23] .
Because our results suggest that alterations in ion transport function alone are insufficient to explain the differences in CD40 expression among different cell lines, we tested the hypothesis that Na/K-ATPase/Src signaling complex might play a role in the regulation of CD40. We have previously shown that knockdown of the a1 isoform of Na/K-ATPase inhibits a1 Na/K-ATPase-mediated signal transduction in PY-17 cells. In contrast, expression of rat a1 fully restores this signaling mechanism in AAC-19 cells [20] . As depicted in Figure 3A , we found that TCB failed to stimulate CD40 expression in PY-17 cells and also failed to induce increases in Src kinase activity. On the other hand, both 100 nM and 1 lM TCB caused a statistically significant increase in CD40 expression in AAC-19 cells ( Figure 3B ; P < 0.05 and P < 0.01, respectively). Moreover, 1 lM TCB also caused a statistically significant increase in Src kinase activity (P < 0.05). Please note that because rat a1 is much less sensitive to TCB than that of pig a1, higher concentrations of TCB were used in this experiment [29] .
The above experiments suggest that signaling through the a1 Na/K-ATPase/Src complex may be important for regulation of CD40 expression. To further test this hypothesis, we determined the effect of pNaKtide, a specific inhibitor of the a1 Na/ K-ATPase/Src complex [30, 31] , on TCB-induced CD40 expression in LLC-PK1 cells. As depicted in Figure 3C , pNaKtide pretreatment inhibited TCB-induced increases in both CD40 expression and Src kinase activity. To substantiate the above findings, we measured CD40 expression in a unique cell line that expresses a mutant a2 isoform of Na/K-ATPase with a gain-of-Src binding capability. Our prior studies have identified two putative Src binding sites in a1 Na/K-ATPase, sites that are completely conserved in mammalian a1. In contrast, the lack of these binding sites are also conserved in mammalian a2 Na/K-ATPase (publication under review). Substitution of four amino acids in a2 Na/KATPase into the corresponding a1 sequence resulted in a mutant a2 that possesses two a1-like Src binding sites. Transfection of PY-17 cells with this mutant a2 generated a stable cell line, named LY-a2, which responds to ouabain stimulation (publication under review) ( Table 2) . Our results, shown in Figure 4A , indicated that gain-of-a2 Src binding capabilities was sufficient to restore the expression of CD40 to a level similar to that in AAC-19 cells.
To further verify the importance of Src binding, we next measured CD40 expression in a novel loss-of-Src binding a1 Na/K-ATPase cell line. This cell line was generated by introducing a single amino acid substitution at alanine 425 (A425P), which has been shown to effectively disrupt the interaction between the a1 isoform of Na/K-ATPase and Src, abolishing ouabain-induced signal transduction [23] (Table 2 ). When we compared the basal CD40 expression in this mutant cell line with AAC-19 cells, we observed that there was a statistically significant reduction in CD40 expression ( Figure 4B ; P < 0.01). Importantly, the a1 expression in this cell line was comparable to the a1 expression in AAC-19 cells.
Na/K-ATPase regulates surface CD40 expression and function
Because CD40 is a transmembrane receptor [8] , we reasoned that overall changes in CD40 expression may not be of functional relevance if surface expression of CD40 remained unaltered in our various mutant cell lines. To address this, we utilized a surface protein biotinylation assay to specifically assess surface expression of CD40. Much like what was observed with regards to total levels of CD40, our results show that LX-a2 cells expressed statistically significant lower amounts of surface CD40 compared with AAC-19 and LY-a2 cells ( Figure 5 ; P < 0.05). To ensure that cytosolic proteins were not biotinylated, we tested for expression of HSP60 and ERK1/ 2 in both surface and total preparations. No significant amounts of HSP60 or ERK1/2 were found in biotinylated preparations (Supplementary data, Figure S2 ). Next, because we observed differences in surface CD40, we assessed whether disruption of the Na/K-ATPase/Src complex affected downstream CD40 signaling pathways. It has been previously established that activation of CD40 in proximal tubule cells leads to an increase in MCP-1, a pro-inflammatory molecule [10] . In order to test whether disruption of the Na/KATPase/Src complex reduces CD40 signaling-induced MCP-1 expression, we activated CD40 signaling pathways in LLC-PK1 cells using sCD40L. As illustrated in Figure 6A , a statistically significant increase in MCP-1 expression was observed with 100 ng/mL of sCD40L by real-time qPCR (P < 0.01). In contrast, in PY-17 cells, which we have shown to have reduced basal CD40 expression, there was no statistically significant change in MCP-1 expression ( Figure 6B ). In AAC-19 cells, 100 ng/mL sCD40L caused a statistically significant increase in MCP-1 messenger RNA (mRNA) expression, although the magnitude of the increase was less than what was observed in LLC-PK1 cells ( Figure 6C ; P < 0.01). As shown in Figure 6D , our pump-functional, Na/K-ATPase/Src signaling deficient, LX-a2 cells had no change in MCP-1 expression following sCD40L treatment, which mirrors what was observed in PY-17 cells ( Figure 6B ). Finally, in our a2 gain-of-function mutant cell line, LY-a2, the effects of sCD40L on MCP-1 expression were restored ( Figure 6E ; P < 0.01). Finally, to rule out the possibility that the lack of response in sCD40L treated PY-17 and LX-a2 cells was due to a general defect in MCP-1, we incubated all cell lines with 10 ng/mL TNF-a for 24 h. By comparing the DDC T of control versus TNF-a-treated cells, our results demonstrate that although not statistically significant, there was a trend towards LLC-PK1 cells having the largest increase in MCP-1 mRNA expression following incubation with TNF-a ( Figure  6F ). Moreover, PY-17, AAC-19 and LY-a2 cells all had similar levels of induction in MCP-1 mRNA expression ( Figure 6F ). Somewhat surprisingly, we observed that although LX-a2 still responded to TNF-a by increasing MCP-1 mRNA expression (by about two cycles), the magnitude of increase was statistically significantly lower as compared with the other tested cell lines ( Figure 6F ). This suggests that the lack of response to sCD40L in LX-a2 but not PY-17 cells may be due in part to a general defect in MCP-1 regulation.
Both Na/K-ATPase and CD40 are known to reside in caveolae [18, 19] . We therefore tested whether disruption of the Na/K-ATPase/Src signaling complex affected the cellular localization of these receptors. We followed a previously established protocol of bicarbonate extraction and sucrose density centrifugation to fractionate cell lysates [32] . We observed that caveolin-1 ( Figure 7A ), a structural protein of caveolae, resided in low-density fraction 4/5 in AAC-19 and LX-a2 cells. a2 Na/K-ATPase ( Figure 7B ) and Src ( Figure 7C ) migrated away from fraction 4/5 in LX-a2 cells but not in AAC-19 cells, as previously reported (publication under review). Interestingly, CD40 remained concentrated in low-density fraction 4/5 in both AAC-19 and LX-a2 cells ( Figure 7D ).
Na/K-ATPase regulates CD40 expression at the posttranscriptional level
To further characterize the relationship between the Na/KATPase/Src signaling complex and CD40, we assessed the basal CD40 mRNA expression in our different cell lines. Interestingly, in contrast to what was seen at the protein level, we observed no statistically significant differences in baseline CD40 mRNA expression ( Figure 8A and B) . Moreover, TCB incubation was unable to induce changes in LLC-PK1 mRNA expression ( Figure 8C ). Therefore this suggests that the Na/KATPase/Src signaling complex regulates CD40 expression at the posttranscriptional level. Thus we treated AAC-19 cells and LXa2 with 10 mg/mL cycloheximide for 24 h and compared the effects of protein synthesis inhibition on basal CD40 expression between these two cell lines. We observed that 10 mg/mL cycloheximide induced a statistically similar degree of degradation of CD40 in both AAC-19 and LX-a2 cells ( Figure 8D ).
D I S C U S S I O N
We report the identification of a novel Na/K-ATPase a1-mediated CD40 regulatory pathway. In particular, we identify the a1 Na/K-ATPase/Src complex as an integral part of this regulatory mechanism, as disruption or blockade of the Na/K-ATPase/Src complex leads to dysregulated basal CD40 and inhibition of CTS-mediated increases in CD40 expression. We further demonstrate that disruption of the Na/K-ATPase/Src complex causes a reduction in surface CD40 expression and affects downstream CD40 signaling pathways.
Interestingly, our data supports the hypothesis that it is not necessarily the absolute degree of Src kinase activity that is critical in regulation of CD40 per se, as we observed that in both PY-17 and LX-a2 cells there was increased basal Src kinase activity but reduced basal expression of CD40. Instead, we hypothesize that the functional status of the Na/K-ATPase/Src signaling complex is the critical factor in the regulation of CD40 expression and function. A similar phenomenon has been previously described in the literature as greater levels of Src kinase activity, in the setting of a disrupted Na/K-ATPase/ Src signaling complex, were paradoxically associated with diminished cellular proliferation and cell spreading, two processes known to be regulated by Src [23] .
Somewhat surprisingly, we were unable to observe any statistically significant changes in the expression of CD40 at the mRNA level with any of our manipulated Na/K-ATPase cell lines or with the use of TCB as a Na/K-ATPase/Src signaling agonist ( Figure 8 ). This suggests a posttranscriptional regulatory mechanism. Moreover, the effects of cycloheximide on CD40 expression in AAC-19 and LX-a2 cells were similar. We have previously demonstrated that CTS-induced increases in a1 were mediated through the mammalian target of rapamycin (mTOR) pathway, a pathway that is known to be involved in the regulation of mRNA translation [33] . Whether the Na/KATPase/Src complex regulates CD40 expression in a similar fashion by affecting the rate of protein translation is the subject of future studies.
CD40 lacks intrinsic kinase domains and requires both caveolae and Src family kinases to mediate signaling [9, 18, [34] [35] [36] [37] . We have previously demonstrated that the Na/K-ATPase/Src complex plays a critical role in caveolin-1, an important structural component of caveolae trafficking [32] . In accordance with previous publications, we observed that in LX-a2 cells, lack of a functional Na/K-ATPase/Src complex led to changes in the localization of Na/K-ATPase a2 and Src from caveolae into higher-density fractions. Interestingly, CD40 remained localized in caveolar fractions in both AAC-19 and LX-a2 cells. Therefore, although the Na/K-ATPase/Src complex is critical in the regulation of CD40 expression and function, disruption of this complex does not affect CD40 localization. On the other hand, our results show that CD40 signaling pathways are disrupted in LX-a2 cells, as sCD40L failed to stimulate an induction in MCP-1. We hypothesize that this may be due in part to the fact that, in these cells, surface CD40 expression was decreased and a subset of Src was no longer located within caveolae. Loss of this caveolar Src may disrupt the ability of CD40 to interact with Src and activate downstream signaling cascades. To this end, it has been previously demonstrated that Na/KATPase interacts with and facilitates signaling of another intrinsic kinase-less receptor in caveolae, scavenger receptor CD36, in a similar fashion [38, 39] . However, it is important to note that LX-a2 cells may have generalized defects in MCP-1 regulation. Therefore, MCP-1 may not be the most appropriate marker for CD40 signaling in this particular cell line. CD40 has been implicated in the pathogenesis of renal fibrosis. Previous studies from our group and others have demonstrated that plasminogen activation inhibitor-1 (PAI-1) as well as the Src family kinase Lyn are both involved in CD40-mediated renal fibrosis [14, 40, 41] . Interestingly, it has been demonstrated that in vascular smooth muscle cells, ROS play an important role in the regulation of CD40 and that activation of CD40 leads to subsequent ROS generation [42, 43] . Moreover, FIGURE 7: Disruption of the Na/K-ATPase/Src complex does not alter CD40 localization. Cell lysates from AAC-19 and Lx-a2 cells were collected and subjected to fractionation by sucrose gradient centrifugation as described in the 'Materials and Methods' section. An equal volume was loaded for fractions 4/5-11. Cellular localization of (A) caveolin-1, (B) Na/K-ATPase a1 or a2, (C) Src and (D) CD40 was analysed by western blot. A western blot representative of at least three independent experiments is shown. and (E) LY-a2 cells were serum starved and treated with sCD40L (0, 10, 50 and 100 ng/mL) for 24 h. Change in MCP-1 expression was measured by real-time qPCR. Results were normalized using levels of b-actin mRNA as a loading control and expressed as a fraction of the control using the comparative CT method (2 ÀDDCT ). The data are presented as mean 6 SE. **P < 0.01 compared with control. (F) LLC-PK1, PY-17, AAC-19, LX-a2 and LY-a2 were serum starved and treated with 10 ng/mL TNF-a for 24 h. Change in MCP-1 expression was measured by real-time qPCR. Results were normalized using levels of b-actin mRNA as a loading control and are expressed using the DDC T method. recent studies have begun to unravel a complex relationship between the Na/K-ATPase/Src complex, ROS and CTS. Specifically, it has been demonstrated that CTS-induced activation of the Na/K-ATPase/Src complex is mediated in part by ROS signaling and that ROS can activate Na/K-ATPase/Src signaling cascades directly [44] [45] [46] . Given the large body of literature implicating ROS as a key player in the pathogenesis of renal fibrosis [47] [48] [49] , we speculate that ROS may be a potential driver in a Na/K-ATPase/CD40 profibrotic feed-forward loop ( Figure 9 ). Importantly, it has been shown that pNaKtide is capable of attenuating Na/K-ATPase/Src-mediated ROS signaling in an obesity model in vivo [50] . Moreover, we show here that pNaKtide can block CTS-induced increases in CD40 expression in vitro. Critically, the in vivo utility of pNaKtide in suppressing the Na/K-ATPase/CD40 signaling axis and its potential effect on renal fibrosis still needs to be evaluated.
In short, we have uncovered a novel CD40 regulatory pathway. Our results have identified a critical role for the a1 isoform of Na/K-ATPase in the regulation of CD40 expression and function. It should be noted that a number of specific details The change in CD40 mRNA expression was analyzed by real-time qPCR. Results were normalized using levels of b-actin mRNA as a loading control and expressed as a fraction of the control using the comparative CT method (2 ÀDDCT ). (D) AAC-19 and LX-a2 were treated with 10 mg/ mL cycloheximide for 24 h. The change in CD40 protein expression was analyzed by western blotting. Results were normalized using a-tubulin as a loading control and are expressed as a fraction of the control. The data are presented as mean 6 SE. **P < 0.01 compared with control. regarding the precise mechanism of this regulatory process remain unanswered. Yet, given the known importance of both of these signaling molecules in the pathogenesis of renal fibrosis, our results provide evidence of a profibrotic feed-forward signaling loop between Na/K-ATPase and CD40. Future endeavors will evaluate the therapeutic potential of pharmacological blockade of the Na/K-ATPase/CD40 signaling dyad for renal fibrosis. We would like to thank Dr Zijian Xie for providing us with the mutant Na/K-ATPase cell lines.
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